| http://dbpedia.org/ontology/abstract
|
Synairgen is a University spin-off and pub … Synairgen is a University spin-off and public limited company (plc) working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and . The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19. Richard Marsden was appointed chief executive officer in September 2009.chief executive officer in September 2009.
|
| http://dbpedia.org/ontology/foundedBy
|
http://dbpedia.org/resource/Stephen_Holgate_%28physician%29 +
, http://dbpedia.org/resource/Donna_E._Davies +
|
| http://dbpedia.org/ontology/foundingYear
|
2003
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Drug_discovery +
|
| http://dbpedia.org/ontology/wikiPageID
|
64658503
|
| http://dbpedia.org/ontology/wikiPageLength
|
9135
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1105003998
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Stephen_Holgate_%28physician%29 +
, http://dbpedia.org/resource/Interferon +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Respiratory_disease +
, http://dbpedia.org/resource/United_Kingdom +
, http://dbpedia.org/resource/Category:Companies_based_in_Southampton +
, http://dbpedia.org/resource/Southampton +
, http://dbpedia.org/resource/National_Institutes_of_Health +
, http://dbpedia.org/resource/Coronavirus_disease_2019 +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/University_of_Southampton +
, http://dbpedia.org/resource/Drug_discovery +
, http://dbpedia.org/resource/Public_limited_company +
, http://dbpedia.org/resource/Category:Companies_established_in_2003 +
, http://dbpedia.org/resource/National_Institute_of_Allergy_and_Infectious_Diseases +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/University_spin-off +
, http://dbpedia.org/resource/Donna_E._Davies +
|
| http://dbpedia.org/property/founder
|
Stephen Holgate
, Donna E. Davies
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Drug_discovery +
, http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
Phillip Monk
, John Ward
, Richard Marsden
|
| http://dbpedia.org/property/locationCity
|
http://dbpedia.org/resource/Southampton +
|
| http://dbpedia.org/property/locationCountry
|
http://dbpedia.org/resource/United_Kingdom +
|
| http://dbpedia.org/property/name
|
Synairgen PLC
|
| http://dbpedia.org/property/tradedAs
|
AIM: SNG
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Start_date +
, http://dbpedia.org/resource/Template:URL +
, http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:Ill +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Companies_established_in_2003 +
, http://dbpedia.org/resource/Category:Companies_based_in_Southampton +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Synairgen?oldid=1105003998&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Synairgen +
|
| http://xmlns.com/foaf/0.1/name
|
Synairgen PLC
|
| owl:sameAs |
https://global.dbpedia.org/id/44Swg +
, http://www.wikidata.org/entity/Q43895224 +
, http://dbpedia.org/resource/Synairgen +
|
| rdf:type |
http://schema.org/Organization +
, http://www.wikidata.org/entity/Q43229 +
, http://dbpedia.org/ontology/Organisation +
, http://www.wikidata.org/entity/Q4830453 +
, http://dbpedia.org/ontology/Agent +
, http://www.wikidata.org/entity/Q24229398 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://dbpedia.org/ontology/Company +
|
| rdfs:comment |
Synairgen is a University spin-off and pub … Synairgen is a University spin-off and public limited company (plc) working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and . The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19. Richard Marsden was appointed chief executive officer in September 2009.chief executive officer in September 2009.
|
| rdfs:label |
Synairgen
|
